Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Chemours
CC
Market cap
$2.16B
Overview
Fund Trends
Analyst Outlook
Journalist POV
14.42
USD
+0.66
4.8%
At close
Updated
Oct 15, 4:00 PM EDT
Pre-market
After hours
14.40
--0.02
0.14%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
4.8%
5 days
-4.12%
1 month
-16.45%
3 months
9.49%
6 months
29.79%
Year to date
-13.7%
1 year
-26.09%
5 years
-37.17%
10 years
103.96%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
55.6%
Negative
Positive
Neutral
Negative
Negative
The Motley Fool
9 days ago
Luminus Trims Its Hefty Chemours Position
Luminus Management LLC reduced its stake in The Chemours Company (CC -1.86%) during Q3 2025, selling shares worth an estimated $4.30 million, based on the average quarterly price, according to an SEC filing dated October 3, 2025.
Neutral
MarketBeat
11 days ago
3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Price action is one of the most important metrics to watch out for when deciding whether a potential investment setup is bullish or bearish. However, despite its importance, price action is only half the picture because relying solely on it without linking to fundamental reasons risks capital blindly.
Neutral
Business Wire
1 month ago
Chemours Announces Board Leadership Appointments: Mary Cranston Named Chair, Alister Cowan Named Lead Independent Director
WILMINGTON, Del.--(BUSINESS WIRE)--The Chemours Company (“Chemours”) today announced that its Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan to the role of Lead Independent Director, effective September 2, 2025. These appointments follow the departure of Dawn Farrell, who has accepted a position with the Canadian government as the Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act. “While.
Neutral
Business Wire
1 month ago
Chemours Publishes 2024 Sustainability Report, Showcasing Latest Progress Against Its 2030 Goals
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Publishes 2024 Sustainability Report, Showcasing Latest Progress Against Its 2030 Goals.
Positive
Zacks Investment Research
1 month ago
Chemours Enters Strategic Agreement With SRF to Boost Supply
CC partners with SRF to expand global supply chain, boost operational flexibility and strengthen its high-value product mix.
Neutral
Business Wire
1 month ago
Chemours and SRF Limited Announce Strategic Agreements in India to Support Market Needs for Essential Applications by 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours and SRF Limited Announce Strategic Agreements in India to Support Market Needs for Essential Applications by 2026.
Neutral
Business Wire
2 months ago
Samsung Electronics Successfully Qualifies Chemours' Opteon™ Two-Phase Immersion Cooling Fluid
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Samsung Electronics Successfully Qualifies Chemours' Opteon™ Two-Phase Immersion Cooling Fluid.
Positive
Zacks Investment Research
2 months ago
Chemours Q2 Earnings & Revenues Beat Estimates on Higher Volumes
CC posts Q2 earnings and sales beat driven by volume and pricing gains, but issues softer sequential guidance.
Positive
Seeking Alpha
2 months ago
Chemours: Solid Q2 And Legal Progress Are Bullish (Rating Upgrade)
Chemours is showing financial improvement, especially in Opteon refrigerants, despite industry headwinds and a recent dividend cut. The company's legal overhang is easing after a favorable New Jersey PFAS settlement, freeing up future cash flow and reducing uncertainty. Balance sheet leverage remains high, but improving free cash flow in the second half should reduce net debt and support the current dividend.
Positive
The Motley Fool
2 months ago
Chemours (CC) Q2 EPS Jumps 53%
Chemours (CC) Q2 EPS Jumps 53%
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close